COVEVOL: Natural Evolution at 6 Months of COVID-19

Many studies have investigated post-COVID symptoms, but the predictors of symptom persistence remain unknown. The objective was to describe the natural course of the disease at 6 months and to identify possible factors favoring the resurgence or persistence of these symptoms. COVEVOL is a retrospect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Louise Messin, Marc Puyraveau, Yousri Benabdallah, Quentin Lepiller, Vincent Gendrin, Souheil Zayet, Timothée Klopfenstein, Lynda Toko, Alix Pierron, Pierre-Yves Royer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	post-COVID-19 “long COVID” risk factors persistent symptoms asthenia dyspnea Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/65f43acba6b64558a3a7668759d0a6f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:65f43acba6b64558a3a7668759d0a6f1
record_format	dspace
spelling	oai:doaj.org-article:65f43acba6b64558a3a7668759d0a6f12021-11-25T19:12:49ZCOVEVOL: Natural Evolution at 6 Months of COVID-1910.3390/v131121511999-4915https://doaj.org/article/65f43acba6b64558a3a7668759d0a6f12021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2151https://doaj.org/toc/1999-4915Many studies have investigated post-COVID symptoms, but the predictors of symptom persistence remain unknown. The objective was to describe the natural course of the disease at 6 months and to identify possible factors favoring the resurgence or persistence of these symptoms. COVEVOL is a retrospective observational descriptive study of 74 patients. All patients with positive SARS-CoV-2 PCR from March 2020 were included. We compared a group with symptom persistence (PS group) with another group without symptom persistence (no-PS group). Fifty-three out of seventy-four patients (71.62%) described at least one persistent symptom at 6 months of SARS-CoV-2 infection. In the PS group, 56.6% were women and the average age was 54.7 years old [21–89.2] ± 16.9. The main symptoms were asthenia (56.6%, <i>n</i> = 30), dyspnea (34%, <i>n</i> = 18), anxiety (32.1% <i>n</i> = 17), anosmia (24.5%, <i>n</i> = 13) and agueusia (15.1% <i>n</i> = 8). Ten patients (13.51%) presented a resurgence in symptoms. Patients in the PS group were older (<i>p</i> = 0.0048), had a higher BMI (<i>p</i> = 0.0071), and were more frequently hospitalized (<i>p</i> = 0.0359) compared to the no-PS group. Odynophagia and nasal obstruction were less present in the inaugural symptoms of COVID-19 in the PS group (<i>p</i> = 0.0202 and <i>p</i> = 0.0332). Persistent post-COVID syndromes are common and identification of contributing factors is necessary for understanding this phenomenon and appropriate management.Louise MessinMarc PuyraveauYousri BenabdallahQuentin LepillerVincent GendrinSouheil ZayetTimothée KlopfensteinLynda TokoAlix PierronPierre-Yves RoyerMDPI AGarticlepost-COVID-19“long COVID”risk factorspersistent symptomsastheniadyspneaMicrobiologyQR1-502ENViruses, Vol 13, Iss 2151, p 2151 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	post-COVID-19 “long COVID” risk factors persistent symptoms asthenia dyspnea Microbiology QR1-502
spellingShingle	post-COVID-19 “long COVID” risk factors persistent symptoms asthenia dyspnea Microbiology QR1-502 Louise Messin Marc Puyraveau Yousri Benabdallah Quentin Lepiller Vincent Gendrin Souheil Zayet Timothée Klopfenstein Lynda Toko Alix Pierron Pierre-Yves Royer COVEVOL: Natural Evolution at 6 Months of COVID-19
description	Many studies have investigated post-COVID symptoms, but the predictors of symptom persistence remain unknown. The objective was to describe the natural course of the disease at 6 months and to identify possible factors favoring the resurgence or persistence of these symptoms. COVEVOL is a retrospective observational descriptive study of 74 patients. All patients with positive SARS-CoV-2 PCR from March 2020 were included. We compared a group with symptom persistence (PS group) with another group without symptom persistence (no-PS group). Fifty-three out of seventy-four patients (71.62%) described at least one persistent symptom at 6 months of SARS-CoV-2 infection. In the PS group, 56.6% were women and the average age was 54.7 years old [21–89.2] ± 16.9. The main symptoms were asthenia (56.6%, <i>n</i> = 30), dyspnea (34%, <i>n</i> = 18), anxiety (32.1% <i>n</i> = 17), anosmia (24.5%, <i>n</i> = 13) and agueusia (15.1% <i>n</i> = 8). Ten patients (13.51%) presented a resurgence in symptoms. Patients in the PS group were older (<i>p</i> = 0.0048), had a higher BMI (<i>p</i> = 0.0071), and were more frequently hospitalized (<i>p</i> = 0.0359) compared to the no-PS group. Odynophagia and nasal obstruction were less present in the inaugural symptoms of COVID-19 in the PS group (<i>p</i> = 0.0202 and <i>p</i> = 0.0332). Persistent post-COVID syndromes are common and identification of contributing factors is necessary for understanding this phenomenon and appropriate management.
format	article
author	Louise Messin Marc Puyraveau Yousri Benabdallah Quentin Lepiller Vincent Gendrin Souheil Zayet Timothée Klopfenstein Lynda Toko Alix Pierron Pierre-Yves Royer
author_facet	Louise Messin Marc Puyraveau Yousri Benabdallah Quentin Lepiller Vincent Gendrin Souheil Zayet Timothée Klopfenstein Lynda Toko Alix Pierron Pierre-Yves Royer
author_sort	Louise Messin
title	COVEVOL: Natural Evolution at 6 Months of COVID-19
title_short	COVEVOL: Natural Evolution at 6 Months of COVID-19
title_full	COVEVOL: Natural Evolution at 6 Months of COVID-19
title_fullStr	COVEVOL: Natural Evolution at 6 Months of COVID-19
title_full_unstemmed	COVEVOL: Natural Evolution at 6 Months of COVID-19
title_sort	covevol: natural evolution at 6 months of covid-19
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/65f43acba6b64558a3a7668759d0a6f1
work_keys_str_mv	AT louisemessin covevolnaturalevolutionat6monthsofcovid19 AT marcpuyraveau covevolnaturalevolutionat6monthsofcovid19 AT yousribenabdallah covevolnaturalevolutionat6monthsofcovid19 AT quentinlepiller covevolnaturalevolutionat6monthsofcovid19 AT vincentgendrin covevolnaturalevolutionat6monthsofcovid19 AT souheilzayet covevolnaturalevolutionat6monthsofcovid19 AT timotheeklopfenstein covevolnaturalevolutionat6monthsofcovid19 AT lyndatoko covevolnaturalevolutionat6monthsofcovid19 AT alixpierron covevolnaturalevolutionat6monthsofcovid19 AT pierreyvesroyer covevolnaturalevolutionat6monthsofcovid19
_version_	1718410159987884032

COVEVOL: Natural Evolution at 6 Months of COVID-19

Ejemplares similares